【摘要】 目的 報道眶內霉菌感染一例。 方法 2011年3月4日收治1例眶內霉菌感染患者，結合文獻分析其臨床特點及診治方法。 結果 患者為47歲女性，有霉菌性鼻竇炎病史，右眼腫脹、視物模糊。經抗真菌治療，病情穩定出院；后多次復發入院，且出現肝腎功能損害。經抗真菌、保肝、保腎、對癥治療，病情穩定出院。 結論 眶內霉菌感染多系鼻竇炎擴散而來，易復發，療程較長，治療過程中應監測肝腎功能。
引用本文：
周娟,張勤,張麗娟,鄒曉毅. 眶內霉菌感染一例并文獻復習. 華西醫學, 2011, 26(12): 1878-1879. doi:
復制
| 1. |
Türel O. Newer antifungal agents[J]. Expert rev anti infect ther, 2011, 9(3): 325-338.
|
| 2. |
Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:perspectives from a maxillofacial surgeon[J]. Clin Microbiol Infect, 2009,15(Suppl 5): 98-102.
|
| 3. |
Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2): 830-832.
|
| 4. |
Walsh T, Anaissie E, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
|
| 5. |
Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents[J]. Clin Infect Dis, 2011, 52(5): 648-653.
|
| 6. |
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(6): 408-415.
|
| 7. |
Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy[J]. Drugs, 2004, 64(18): 1997-2020.
|
| 8. |
Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J].Clin Infect Dis, 2008, 46(2): 201-211.
|
- 1. Türel O. Newer antifungal agents[J]. Expert rev anti infect ther, 2011, 9(3): 325-338.
- 2. Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:perspectives from a maxillofacial surgeon[J]. Clin Microbiol Infect, 2009,15(Suppl 5): 98-102.
- 3. Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2): 830-832.
- 4. Walsh T, Anaissie E, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
- 5. Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents[J]. Clin Infect Dis, 2011, 52(5): 648-653.
- 6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(6): 408-415.
- 7. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy[J]. Drugs, 2004, 64(18): 1997-2020.
- 8. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J].Clin Infect Dis, 2008, 46(2): 201-211.
1/5
微信公眾號
